--- canonical_url: https://www.stockexpertai.com/earnings/iex last_updated: 2026-05-09T14:55:33.420Z --- # IDEX Corporation (IEX) Q4 FY2026 Earnings Preview > This content was automatically generated with FMP live data + Q1 FY2026 earnings call transcript. Generated: 2026-05-09T14:55:33.021Z. Educational tool, not investment advice. --- ## Quick Summary | Field | Value | Source | |---|---|---| | Price | $216.92 (▲ 0.95%) | fmp:quote | | Market Cap | $16.1B | fmp:profile | | 52w range | $157.25 – $223.85 | fmp:quote | | Earnings | Wed 29 Jul | fmp:earnings-history | | EPS estimate | $2.12 (+2% YoY) | fmp:earnings-estimate | | Revenue estimate | $903.3M | fmp:earnings-estimate | | Beat streak | 8/4 | fmp:earnings-history | | Rating | B+ (overall 3/5) | fmp:ratings | | Analyst median target | $250 (+15.2% upside) | fmp:price-target-consensus | | MoonshotScore | 47/100 | derived | | Council | 3/6 bullish | derived | | Munger verdict | Fairly Valued | derived | ## IDEX Corporation — Q4 FY2026 Expectations Q4 consensus: revenue $903.3M^{[FMP est]}, EPS $2.12^{[FMP est]}. 8 consecutive quarters of beat^{[FMP earnings]}. ## Quick Take **Score:** B+ · **Stance:** BUY · **Council:** 3/6 · **Moonshot:** 47 = MoonshotScore 47^{[9-pillar formula]} + Council 3/6^{[6-lens rule]}. Form 4: 0 transactions^{[FMP Form 4]}. ## Watchlist (5 metrics) ### 1. Full Year Organic Growth Guidance For the full year 2026, we now expect organic growth in the 3% to 4% range, an increase over our original 1% to 2% organic growth guidance coming into the year. > "For the full year 2026, we now expect organic growth in the 3% to 4% range, an increase over our original 1% to 2% organic growth guidance coming into the year." > — Sean Gillen, Chief Financial Officer, Expectation / Guide · Q1 FY2026 ### 2. Hst Order Growth Q1 In HST, organic orders increased 17% and revenue grew 11% organically. > "In HST, organic orders increased 17% and revenue grew 11% organically." > — Sean Gillen, Chief Financial Officer, Investor Focus · Q1 FY2026 ### 3. Fmt Order Growth Orders in the Fluid & Metering Technologies (FMT) segment grew 9% organically year-over-year, driven by strong order activity in our water platform and our pumps businesses. > "Finally, orders in our Fluid & Metering Technologies, or FMT segment, grew 9% organic year-over-year. This was driven by strong order activity in our water platform and our pumps businesses." > — Eric Ashleman, President and Chief Executive Officer, Investor Focus · Q1 FY2026 ### 4. Fy26 Guidance Increase IDEX is raising its full year 2026 financial outlook, taking into account Q1 performance and backlog build. > "Taking our Q1 performance and backlog build into account, we are raising our full year 2026 financial outlook." > — Eric Ashleman, President and Chief Executive Officer, Expectation / Guide · Q1 FY2026 ### 5. Share Repurchase Commitment IDEX plans on maintaining the share repurchase level per quarter through the rest of 2026. > "We plan on maintaining the share repurchase level per quarter through the rest of 2026." > — Sean Gillen, Chief Financial Officer, Investor Focus · Q1 FY2026 ## MoonshotScore Pillars | Pillar | Score | Level | Evidence | |---|---|---|---| | Revenue Growth | 1.0 | weak | Q1 vs Q2: growth slowing (+2.5%, below threshold) | | Gross Margin | 4.0 | medium | Q1: average margin (44.9%) | | Operating Leverage | 2.0 | weak | op margin healthy (19.4%) | | Cash Runway | 10.0 | strong | FCF very strong ($0.1B, 4.9× CapEx) | | R&D Intensity | 3.0 | weak | low R&D investment (0.0%, weak innovation) | | Price Momentum | 7.0 | strong | RSI 63.7 positive momentum, 50d above | | News Sentiment | 6.0 | medium | majority buy (56%) | **Formula:** sum(pillar.score) / (count * 10) * 100. Each pillar deterministic from FMP. Source maps in pillar.formula. ## Council (7-Lens) | Name | Stance | Context | |---|---|---| | Ray Dalio | bull | macro · target upside +15.2% | | Ken Griffin | bull | flow · 50d MA above | | Jim Simons | neutral | quant · RSI 64 | | Klarman | neutral | value · target upside +15.2% | | Buffett | bull | quality · ROE score 4/5 | | Munger | neutral | valuation · target upside +15.2% | **Formula:** Each lens uses deterministic rule on bundle data. Logged in member.contextTr. ## Munger Lens - **Verdict:** Fairly Valued - **Financial Health:** Moderate - **Margin of Safety:** Moderate - **Interest Coverage:** Adequate - **ROIC vs WACC:** Healthy **Formula:** verdict=upside>25?Undervalued:>0?Fairly Valued:Overvalued. Each lens deterministic from FMP ratings + priceTarget. ## Technical Levels - **RSI(14):** 63.7 — yükselişte nötr — overbought sınırının altında, momentum pozitif - **50d MA:** $200 — hisse %8.3 üstünde — kısa vadeli destek - **200d MA:** $182 — hisse %19.1 üstünde — uzun vadeli destek - **Volume (10d):** -28% ## Past Performance (4 Quarters) | Quarter | EPS Actual | EPS Estimate | Result | Reaction | |---|---|---|---|---| | Q2 FY25 | $2.07 | $2.00 | BEAT | -0.5% | | Q3 FY25 | $2.03 | $1.93 | BEAT | -1.8% | | Q4 FY25 | $2.10 | $2.04 | BEAT | +0.3% | | Q1 FY26 | $2.00 | $1.78 | +12.4% EPS | +0.2% | Q1 (April 29, 2026): EPS $2.00 vs $1.78 est^[FMP], +12.4% beat. D+1 movement: +0.2%^{[FMP D+1]}. Decline despite beat — market reacted to guidance, not numbers. ## 3 Scenarios ### Scenario A · Beat **Q4 EPS > $2.12 + CapEx discipline** Threshold: EPS > $2.12^{[FMP est]}. Target: Break above median target $250^{[FMP target]}; high target $257^[FMP] upper bound. ### Scenario B · In-Line **EPS ≈ $2.12 + CapEx < $17.7M** Threshold: EPS ≈ $2.12^{[FMP est]}, Q4 CapEx < $17.7M^[FMP]. Target: Consolidation in the band between current $217^[FMP] and median $250^[FMP]. ### Scenario C · Miss **EPS < $2.06 or CapEx ≥ $17.7M** Threshold: EPS < $2.06^{[FMP est×0.97]}. Target: Current $217 below SMA200 $182^[FMP], if rejection continues, $155^[derived] support activates. ## Risk Notes ### Primary segment below threshold Q1: EPS $2.00 vs $1.78 beat^[FMP], stock +0.2% D+1^[FMP]. ### Backlog concentration No RPO/backlog concentration disclosed in Q1 earnings call. ### Insider trading Form 4 data is marked in the table — this page does not generate assumptions for this stock. | Executive | Action | Amount | Date | |---|---|---|---| **Net:** — (0 transactions · 0 sells · 0 buys) · Q1 FY26 ### CapEx shock Q1 CapEx $17.7M^{[FMP cashflow]}. Q1 op margin 19.4%^{[FMP op margin]} — this level in Q4 is sensitive to CapEx revision risk. ## Wall Street Consensus - **Median target:** $250 (+15.2% upside vs current $217) - **High / Low:** $257 / $214 - **Buy / Hold / Sell:** 9 / 7 / 0 - **Analyst count:** 8 (last quarter), 33 all-time ## Additional Transcript Insights ### 1. fy26_guidance_increase **Claim:** IDEX is raising its full year 2026 financial outlook, taking into account Q1 performance and backlog build. **Evidence (transcript):** "Taking our Q1 performance and backlog build into account, we are raising our full year 2026 financial outlook." **Numbers:** 2026 ### 2. hst_growth_drivers **Claim:** Growth in the Health & Science Technologies (HST) segment is fueled by high-value applications in data center, semiconductor, and space and defense markets. **Evidence (transcript):** "Strength was most pronounced in our Health & Science Technologies, or HST segment, where secular drivers continue to fuel growth across high-value applications in data center, semiconductor and space and defense markets." **Numbers:** — ### 3. fmt_order_growth **Claim:** Orders in the Fluid & Metering Technologies (FMT) segment grew 9% organically year-over-year, driven by strong order activity in our water platform and our pumps businesses. **Evidence (transcript):** "Finally, orders in our Fluid & Metering Technologies, or FMT segment, grew 9% organic year-over-year. This was driven by strong order activity in our water platform and our pumps businesses." **Numbers:** 9% ### 4. share_repurchase_commitment **Claim:** IDEX plans on maintaining the share repurchase level per quarter through the rest of 2026. **Evidence (transcript):** "We plan on maintaining the share repurchase level per quarter through the rest of 2026." **Numbers:** 2026 ### 5. hst_order_growth_q1 **Claim:** In HST, organic orders increased 17% and revenue grew 11% organically. **Evidence (transcript):** "In HST, organic orders increased 17% and revenue grew 11% organically." **Numbers:** 17%, 11% ### 6. full_year_organic_growth_guidance **Claim:** For the full year 2026, we now expect organic growth in the 3% to 4% range, an increase over our original 1% to 2% organic growth guidance coming into the year. **Evidence (transcript):** "For the full year 2026, we now expect organic growth in the 3% to 4% range, an increase over our original 1% to 2% organic growth guidance coming into the year." **Numbers:** 3%, 4%, 1%, 2%, 2026 --- *Data source: FMP (live query, 2026-05-09), Q1 FY2026 earnings call transcript (Translated to EN with Gemini 2.0 Flash). Educational tool, not investment advice.*